Globus strengthens position as UK's leading force in hand protection

Published: 5-Mar-2010
Personal Protection Regulatory

Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.

Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.

From 1 March 2010 Globus has taken over all Showabest activities in the UK and Ireland. The addition of unique chemical protection products and the world's most advanced disposable glove offer gives Globus the only product portfolio that can claim the original iconic styles that created totally new markets for their distribution partners.

Grip style gloves, Palm Fit technology, Dyneema cut protective gloves and the world's first and patented disposable nitrile glove were all created by the Showabest organisation.

Innovative sales & marketing techniques have seen Globus rise to the forefront of the hand protection sector. Its customers now look set to enjoy the benefits of an invigorated range supported by UK stock and extensive sales support infrastructure.
  • Companies:
  • Globus (Shetland) Ltd
See more

You may also like

Regulatory

Accelerating and enhancing toxicology assessments

Read more
Infographic guides users through ToxHQ’s speedy assessment features

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  2. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Accelerating and enhancing toxicology assessments

Infographic guides users through ToxHQ’s speedy assessment features
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain

With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
Regulatory

Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license

The licensing deal with Chiome enhances its open innovation platform
Manufacturing

Solvent recycler SPR-200 boosts sustainability in pharma labs

Recycling up to 90% of solvent in isocratic HPLC improves lab efficiency and sustainability
Regulatory

Accumulus Synergy teams up with CEPI to expedite the vaccine regulatory approval process

Through Accumulus' cloud-based technology, the two organisations aim to accelerate the accessibility of data for the regulatory approval process of vaccines globally, enhancing the world's pandemic 'preparedness'
Subscribe now